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Abstract Despite recent advances in the treatment of children
with acute megakaryoblastic leukemia (AMKL) using inten-
sified treatment protocols, clear prognostic indicators, and
treatment recommendations for this acute myeloid leukemia
(AML) subgroup are yet to be defined. Here, we report the
outcome of 97 pediatric patients with de novo AMKL (ex-
cluding Down syndrome [DS]) enrolled in the prospective
multicenter studies AML-BFM 98 and AML-BFM 04
(1998-2014). AMKL occurred in 7.4 % of pediatric AML
cases, at younger age (median 1.44 years) and with lower
white blood cell count (mean 16.5×109/L) as compared to
other AML subgroups. With 60±5 %, children with AMKL
had a lower 5-year overall survival (5-year OS; vs. 68±1 %,
Plog rank=0.038). Yet, we achieved an improved 5-year OS in
AML-BFM 04 compared to AML-BFM 98 (70±6 % vs. 45±
8 %, Plog rank=0.041). Allogeneic hematopoietic stem cell
transplantation in first remission did not provide a significant
survival benefit (5-year OS 70±11 % vs. 63±6 %; PMantel-
Byar=0.85). Cytogenetic data were available for n=78 pa-
tients. AMKL patients with gain of chromosome 21 had a
superior 5-year OS (80±9 %, Plog rank=0.034), whereas trans-
location t(1;22)(p13;q13) was associated with an inferior 5-
year event-free survival (38±17 %, Plog rank=0.04). However,
multivariate analysis showed that treatment response (bone
marrow morphology on day 15 and 28) was the only indepen-
dent prognostic marker (RR=4.39; 95 % CI, 1.97–9.78). In-
terestingly, GATA1-mutations were detected in six patients
(11 %) without previously known trisomy 21. Thus, AMKL
(excluding DS) remains an AML subgroup with inferior out-
come. Nevertheless, with intensive therapy regimens, a steep
increase in the survival rates was achieved.
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Introduction
Acute megakaryoblastic leukemia (AMKL), M7 according to
the French-American-British (FAB) classification [1], is a spe-
cific subtype of acute myeloid leukemia (AML) that can be
clearly distinguished from other subtypes because of its bio-
logical and clinical characteristics. Morphologically, AMKL
blasts typically show cytoplasmic blebs, which are
immunophenotypically positive for CD41, CD42b, and
CD61. Myelofibrosis and manifestation as extramedullary
disease are common features of AMKL and often hamper
diagnosis.
AMKL occurs predominantly in childhood and particularly
in children with Down syndrome (DS) [2–5], accounting for
approximately 10 % of pediatric AML cases. In contrast to
DS-AMKL (∼80 % survival), non-DS-AMKL is an AML
subgroup associated with poor prognosis. For some studies,
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survival rates of only 14–36 % were reported [5–7], whereas
for other studies, survival rates of 50–70 % were reported [6,
8]. Within the AML-BFM studies, the poor outcome of non-
DS-AMKL in the AML-BFM 87 trial (5-year event-free sur-
vival [5-year EFS] 11±7 %, 5-year overall survival [5-year
OS] 21±9 %) could be improved by intensifying the therapy
in the AML-BFM 93 and 98 trials (5-year EFS 41±6 %, 5-
year OS 49±6%) [2]. However, despite recent advances in the
treatment, the optimal treatment strategy remains controver-
sially discussed. Whereas some study groups treat non-
DS-AMKL as very high risk, recommending allogeneic
hematopoietic stem cell transplantation (HSCT) during
first complete remission (CR1) [5], other study groups
obtained superior survival rates with intensive chemo-
therapy alone, which were not further increased by al-
logeneic HSCT [8].
Similarly, the prognostic impact of cytogenetically defined
subgroups could not be clearly defined, mostly due to the
small size of the study cohorts. A limited number of specific
genetic abnormalities characterizes non-DS-AMKL. Translo-
cation t(1;22), which creates the RBM15-MKL1 (alias:
OTT1/MAL) fusion protein, is unique to pediatric AMKL
[9, 10]. While the St. Jude AML 02 study proposed t(1;22)
(n=5) as a good prognostic marker [6], other studies sug-
gested the opposite [9]. Also, the prognostic value of other
frequently observed cytogenetic aberrations—such as com-
plex karyotype, trisomy 8, 19, or 21, MLL-rearrangements,
loss of chromosome 7 or 7q-, or der(3q)—remains open. Here,
we report the clinical, cytogenetic, and therapeutic data of 97
children with non-DS-AMKL, treated uniformly according to
the two sequential prospective multicenter studies AML-BFM
98 and AML-BFM 04.
Patients and methods
Patients
The AML-BFM 98 and AML-BFM 04 studies were random-
ized, controlled phase III studies running in 75 centers in
Germany, Austria, Switzerland, and the Czech Republic.
The AML-BFM 98 study opened in July 1, 1998 and closed
in June 30, 2003. Between July 1, 2003 and April 30,
2004, the AML-BFM 98 Interim Study, continuing the
best arm of the AML-BFM 98 trial, recruited further
patients. The AML-BFM 04 study opened in April
2004 and closed in February 2014. The final protocols were
approved by the protocol review committee of the German
Cancer Aid (DKH) and by the ethics committee of the Uni-
versity of Münster.
Simultaneously, Germany, Austria, and Switzerland
(BFM-Core group) participated in the prospective study on
allogeneic HSCT vs. chemotherapy for high-risk (HR)
childhood AML in first complete remission (AML CR1
HLA id) on behalf of the European Bone Marrow Transplan-
tation (EBMT) Pediatric Working Party and the International
BFM Study Group (I-BFMSG), which was approved by the
ethics committee of the University of Tübingen. HR patients
and family members were required to undergo HLA typing
after the assignment to the risk group. All HR patients with a
matched sibling donor were eligible for allogeneic HSCT in
first complete remission.
The French-American-British (FAB) classification was
used for the initial diagnosis of AML [1]. The diagnoses of
the FAB M0 and M7 subtypes required confirmation by im-
munologic methods [1, 11]. To characterize childhood acute
megakaryoblastic leukemia, we reviewed 97 patients, diag-
nosed with AMKL by the BFM Study Group in the studies
AML-BFM 98 (n=37) and AML-BFM 04 (n=60), including
patients younger than 18 years with de novo AMKL. Patients
with DS, myelosarcoma, secondary AML, or pretreatment of
more than 2 weeks were excluded.
Treatment plan
Children with non-DS-AMKL were treated according to re-
gimes AML-BFM 98 and AML-BFM 04, being similar for
most parts (Fig. 1).
In AML-BFM 98, patients received chemotherapy with an
induction of cytarabine (Ara-C), idarubicin, and etoposide
(AIE) and thereafter HAM (high-dose cytarabine,
mitoxantrone, cytarabine i.th.), followed by a randomized
consolidation therapy (i.e., AI [cytarabine, idarubicin,
cytarabine i. th.] and haM [high-dose cytarabine,
mitoxantrone, cytarabine i.th.] or the BFM-type 6-week con-
solidation [6-thioguanine, prednisone, vincristine, idarubicin,
cytarabine, cyclophosphamide, cytarabine i.th.]).
In AML-BFM 04, patients received a randomized induc-
tion therapy of cytarabine (Ara-C), liposomal daunorubicin
(L-DNR), and etoposide (ADxE) or AIE [12]. After the sec-
ond induction with HAM, consolidation therapy was random-
ized by introducing 2-CDA (2-chloro-2-deoxyadenosine) to
AI as intensification [12–14].
Allogeneic HSCT should be performed in CR1 after con-
solidation according to the AML CR1 HLA id protocol. Chil-
dren who were not transplanted in CR1 received one course of
HAE as an intensification therapy (high-dose cytarabine and
etoposide) and 1-year maintenance therapy (12 months;
thioguanine, cytarabine, cytarabine i.th.). After 2006, the in-
dication for allogeneic HSCT was restricted to patients with
BMblasts >5% after second induction. Allogeneic HSCTwas
performed in 23 SCT centers as reported previously [15]. The
recommended standard conditioning regimen for allogeneic
HSCT in first complete remission was busulfan and
cyclophosphamide.
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Cytogenetic and molecular genetic analyses
Cytogenetic analyses were carried out and centrally reviewed
in the AML-BFM reference laboratory in Giessen (AML-
BFM 98) and Hannover (AML-BFM 04), Germany, as previ-
ously described [16]. Comprehensive cytogenetic data from
80 % (n=78) of the included patients (n=97) were available.
Complete karyotypes were described according to the Inter-
national System of Human Cytogenetic Nomenclature [17]. In
the AML-BFM 04 study, sequencing of GATA1 was prospec-
tively performed as previously described [18]. For 15 patients
diagnosed before 2004, material was available for retrospec-
tive sequencing analysis.
Statistics
Complete remission (CR) was defined by fulfillment of the
Cancer and Leukemia Group B (CALGB) criteria [19], early
death (ED) being death before or within the first 6 weeks of
treatment. Event-free survival (EFS) was defined as time from
diagnosis to the first event. Events were death from any cause,
early death, failure to achieve remission, relapse, and second-
ary malignancy. Failure to achieve remission was considered
as an event on day 0. Survival was defined as the time of
diagnosis to death from any cause.
The Kaplan-Meier method was used to estimate survival
rates [20]. Differences were compared with the 2-sided log-
rank test [21]. Standard errors (SEs) were obtained using
Greenwoods formula. Cumulative incidence of relapse and
death in CR were calculated by the method of Kalbfleisch
and Prentice and compared with Gray’s test. The Cox propor-
tional hazards model has been used to obtain the estimates and
the 95 % confidence interval of the relative risk for prognostic
factors [22]. Differences in the distribution of individual pa-
rameters among patient subsets were analyzed using the chi-
squared test or Fisher’s exact test for categorized variables and
the Mann-Whitney U test for continuous variables. The effect
of HSCT on survival was tested using the Mantel-Byar meth-
od for comparisons of patients treated or not treated with
HSCT. For graphic presentation, patients without HSCT and
EFS below the median time to transplantation (0.4 years) were
excluded. Follow-up was as of June 2014. Computations were
performed using SAS (Statistical Analysis System Version
9.3; SAS Institute, Cary, NC).
Results
Patient characteristics
Of 1316 pediatric patients with AML enrolled in the
population-based studies AML-BFM 98 and AML-BFM 04,
97 (7.4 %) presented with de novo non-DS-AMKL. Patient
characteristics are summarized in Table 1. The median age at
diagnosis was 1.44 years (range 0–15 years), being notably
younger than for other AML subtypes (9.98 years; PFisher’s<
0.0001). The mean white blood cell (WBC) count of children
with de novoAMKL (16.5×109/L) was lower than of children
with other AML subtypes (58.5×109/L). Additionally, initial



















































Fig. 1 Treatment schedule of AML-BFM 98 and AML-BFM 04 studies
for high-risk patients. AIE cytarabine/idarubicin/etoposide; ADxE
cytarabine/l-daunorubicin/etoposide; HAM high-dose cytarabine (3 g/
m2 q12h over 3 days)/mitoxantrone; AI cytarabine/idarubicin; AI/2-
CDA cytarabine/idarubicin/2-chloro-2-deoxyadenosine; haM high-dose
cytarabine (1 g/m2 q12h over 3 days)/mitoxantrone; consolidation 6-
thioguanine/prednisone/vincristine/idarubicin/cytarabine/cyclophospha-
mide; HAE high-dose cytarabine (3 g/m2 q12h over 3 days)/
etoposide; MSD matched sibling donor; asterisk indicates until 2006;
CNS irradiation; maintenance 12 months thioguanine/cytarabine; R1
first random assignment; R2 second random assignment; R3 third ran-
dom assignment
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AML subtypes (12.4 %) than among AMKL patients (2.1 %).
Patients with AMKL frequently presented with a longer dis-
ease history. Only 41.8 % of AMKL patients had an anamne-
sis less than 3 weeks, as compared to 57.2 % of children with
other AML subtypes.
Comparing AML-BFM 98 and AML-BFM 04, the study
population did not significantly differ. We only noted statisti-
cal significance in the mean WBC of 19.7×109/L vs. 14.5×
109/L (P=0.002).
Treatment outcome
With a 5-year OS of 60±5 % (Fig. 2) and 5-year EFS of 47±
5 %, children with AMKL revealed a significantly poorer
outcome as compared to the total group of children with other
AML subtypes (Fig. 2; 5-year EFS 52±1 %, Plog rank=0.079).
The complete remission (CR) rate of non-DS-AMKL patients
was comparable to other children with HR-AML (defined by
the reported criteria of the AML-BFM study group [14, 23]).
Eighty-one patients (83.6 %) achieved CR, 32 % (n=32)
relapsed after first CR, and 4.1 % (n=4) died in first CR.
Thirteen patients (13.4 %) were partial- and non-responders
(PR; NR) to induction therapy and 3.1 % (n=3) suffered from
early death (ED). The cumulative incidence of relapse (CIR)
Table 1 Patient characteristics
AMKL (FAB M7) Other AML subtypes
Total AML-BFM 98 AML-BFM 04 AML-BFM 98+04
N (%) N (%) N (%) Pa N (%) Pb
Gender
Male 53 54.6 21 56.8 32 53.3 625 51.3
Female 44 45.4 16 43.2 28 46.7 0.83 594 48.7 0.52
Age, years
<2 64 66.0 24 64.9 40 66.7 241 19.8
2–5 23 23.7 6 16.2 17 28.3 170 13.9
≥6 10 10.3 7 18.9 3 5.0 0.06 808 66.3 <0.001
WBC, 109/L
<20 75 77.3 24 64.9 51 85.0 631 51.8
>20 22 22.7 13 35.1 9 15.0 0.03 587 48.2 <0.001
CNS involvement
No 92 94.8 35 100.0 57 96.6 1036 87.6
Yes 2 2.1 – – 2 3.4 0.53 147 12.4 <0.001
BM day 15+28
≤5 % of blasts 74 77.9 24 66.7 50 84.7 815 71.1
>5 % of blasts 21 21.1 12 33.3 9 15.3 0.05 331 28.9 0.16
Anamnesis
<3 weeks 38 41.8 16 43.2 22 36.7 680 57.2
≥3 weeks 53 58.2 18 48.6 35 48.3 0.51 508 42.8 0.004
Allo HSCT in 1.CR
Yes 18 22.8 9 27.3 9 18.8 113 89.5
No 63 77.8 24 72.7 39 81.3 0.35 962 10.5 <0.001
aAML-BFM 98 vs. AML-BFM 04








































other AML subtypes (N=1219, 561 events)
AMKL  (N=  97, 52 events)
Fig. 2 Overall survival of patients diagnosed with non-DS de novo
AMKL (n=97) or other AML subtypes (n=1219) in the AML-BFM 98
and AML-BFM 04 studies. Five-year OS is given
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was 45±5 % compared to 39±1 % (PGray=0.07) for patients
with other AML subtypes.
Comparing AML-BFM 98 to AML-BFM 04 (Fig. 1), the
5-year EFS increased and the 5-year OS of AMKL patients
increased significantly from 45±8 % to 70±6 % (Fig. 3a-b),
while CIR decreased from 46±8 % to 23±6 % (Fig. 3c).
Although the introduction of liposomal daunorubicin (L-
DNR or Dx) in the induction of AML-BFM 04 (randomiza-
tion of ADxE vs. AIE) resulted in no significant improvement
regarding 5-year EFS and 5-year OS (56±12 % vs. 52±8 %,
Plog rank=0.84; 74±11 % vs. 68±8 %, Plog rank=0.57), only
15.3 % of AMKL patients in AML-BFM 04 (ADxE and AIE)
displayed a poor treatment response, as assessed by bone mar-
row morphology on day 15 and day 28 of therapy (>5 % blast
cells). This is a clear improvement to AML-BFM 98 with
33.3 % (Table 1). In both cohorts together (AML-BFM 98
and 04), those poor responders had an estimated 5-year OS
of only 35±11 % and 5-year EFS of 12±8 %, while good
responders (≤5 % BM blasts on day 15 and day 28) showed
a 5-year OS of 66±6 % (Plog rank=0.021) and 5-year EFS of
56±6 % (Plog rank=0.0001) (Fig. 4a, b). The introduction of 2-
CDA to the consolidation therapy did not have an impact on
the survival rates on AMKL patients.
Postremission management
Until 2006, allogeneic HSCT in CR1 was recommended for
all patients with an HLA compatible sibling donor. To assess
the therapeutic effect of allogeneic HSCT compared to che-
motherapy alone, we performed as-treated survival analyses
taking time to transplant into account. For graphical display
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AML-BFM 98 Relapse 0.46, SE=0.08 Events/N  17/37
AML-BFM 98 Death in CCR 0.03, SE=0.03 Events/N   1/37
AML-BFM 04 Relapse 0.23, SE=0.06 Events/N  14/60









































Fig. 3 Outcome of AMKL patients in the AML-BFM 98 or AML-BFM
04 studies: a Event-free survival. b Overall survival. c Cumulative inci-
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Fig. 4 Outcome of AMKL patients based on treatment response: a
Event-free survival. b Overall survival. c Cumulative incidence of re-
lapse/death. Five-year probabilities are given. Treatment response was
evaluated by bone marrow morphology (>5 % blasts on day 15 or 28)
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the median time until transplantation (0.4 years) were exclud-
ed. In AML-BFM 98, allogeneic HSCT in CR1 was per-
formed on 9 (27 %) non-DS-AMKL patients, whereas 24
patients (73 %) were treated by chemotherapy alone. In
AML-BFM 04, the percentages were 19 and 81 %. The out-
come was not significantly different in patients undergoing
allogeneic HSCT rather than chemotherapy alone in AML-
BFM 98 (5-year OS: 56±17 % vs. 49±11 %, PMantel-Byar=
0.95; 5-year EFS 44±17 % vs. 45±11 %, PMantel-Byar=0.6)
and AML-BFM04 (5-year OS: 88±12% vs. 72±8%,PMantel-
Byar=0.83; 5-year EFS: 88±12 % vs. 65±8 %, PMantel-Byar=
0.58)(Supplementary Fig. S1). Likewise, we also observed no
benefit from allogeneic HSCTwhen analyzing the total cohort
of AMKL patients (AML-BFM 98 and 04; Fig. 5a, b,
Table 2).
Cytogenetic analyses
Cytogenetic analyses were performed for 78 (80.4 %) children
with non-DS-AMKL (Tables 1 and 2). Of note, neither com-
plex karyotype (three or more independent abnormalities
including at least one structural abnormality), MLL rearrange-
ment nor monosomy 7/7q- was associated with a significantly
worse outcome compared to patients without these aberrations
(Table 2, Supplementary Fig. S2A-C). The translocation
t(1;22)(p13;q13) was found in 8 patients (10.3 %; patient
characteristics summarized in Supplementary Table S1),
who had a significantly worse 5-year EFS (38±17 %) than
patients without this translocation (53±6 %, Plog rank=0.039;
Table 2 and Supplementary Fig. S2D-F).
Other recurrent aberrations were mainly numerical chang-
es, such as gain of chromosome 8 or 21. Gain of chromosome
21 was associated with better survival rates (5-year OS=80±
9 % vs. 54±7 %, Plog rank=0.034; Supplementary Fig. S2G-I).
GATA1-status
Sequencing of the hematopoietic transcription factor GATA1
was performed on 53 patients. None of these children was
previously diagnosed with Down syndrome (constitutional
trisomy 21 or trisomy 21 mosaic) or had a history of transient
abnormal myelopoiesis (TAM) during the neonatal period. Six
patients (11.3 %) were positive for a GATA1-mutation, and a
gain of chromosome 21 in the leukemic blasts was detected
(Table 3). Based on these findings, four patients were diag-
nosed with trisomy 21 mosaic and two with an acquired triso-
my 21. Interestingly, the leukemic blasts of all six patients
showed CD7 surface marker expression (Table 3), a common
feature of DS-AMKL [24]. Two patients with trisomy 21 mo-
saic were treated by the reduced intensity ML-DS 2006
treatment recommendations and are in continuous CR
without additional therapy. From the remaining four pa-
tients, who were treated by standard AML-BFM proto-
cols, one child received matched sibling donor (MSD)
HSCT after NR and another one received HSCT after
CR2 from a mismatched unrelated donor. Each child
with GATA1-mutation maintains in continuous CR
(Table 3).
Multivariate analysis
In the multivariate analysis for 5-year EFS, including sex, age,
WBC more than 20×109/L, BM blasts more than 5 % on day
15 or 28, as well as cytogenetic subgroups (normal and com-
plex karyotype, t(1;22)(p13;q13), gain of chromosome 8 (+8),
gain of chromosome 21 (+21), monosomy 7 and der(3)) as
risk factors, only poor treatment response (>5% blasts after 15
or 28 days; RR=4.39; 95 % CI, 1.97–9.78; Px2=0.0003) was
of independent prognostic significance (Table 4). For translo-
cation t(1;22)(p13;q13), which was statistically significant in
the univariate analysis, multivariate analysis indicated a trend
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Fig. 5 Outcome of AMKL patients assigned to allogeneic HSCT in 1.CR
or to chemotherapy only: a Event-free survival. b Overall survival. Five-
year probabilities are given. Patients who did not receive HSCT and had
an event before the median time until transplantation (0.4 years) were
excluded
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Discussion
The overall outcome of AMKL (excluding DS) was extremely
poor in the early AML-BFM 87 trial (EFS 11±7%, 5-year OS
21±9 %), which could be significantly improved in the fol-
lowing trials AML-BFM 93 and 98 (5-year EFS 41±6 %, 5-
year OS 49±6 %) [2] by introducing idarubicin as well as
high-dose cytarabine plus mitoxantrone to the protocol. With
a 5-year OS of 70±6 % in AML-BFM 04, we now achieved
the highest survival rate for pediatric non-DS-AMKL patients
within the BFM studies.
Our study with 97 patients demonstrates that AMKL is
nowadays not necessarily associated with a poor outcome,
as we and others previously reported (Athale 2001: SJCRH,
n=28, 2-year EFS/OS 14/14 %; O’Brien 2013: AML02 (n=
26), 3-year EFS/OS 49/54 %; POG 9421 (n=49), 5-year EFS/
OS 35/36 %; Barnard 2007: CCG 2891 (n=53), 5-year EFS/
OS 23/28 %) [5–7]. Although we confirmed that AMKL con-
stitutes an AML subgroup with inferior outcome compared to
the whole group of AML patients, we could achieve a steep
increase in the survival rates by continuous development of
the AML-BFM therapy protocols. These results support a
Japanese study on a cohort of 21 patients with AMKL,
reporting 10-year EFS and OS of 57 and 76 %, respectively
[8]. Hence, intensification of the already very intensive thera-
py regimen and better supportive care may result in improved
prognosis in AMKL patients.
Interestingly, the improved survival rates of the AML-
BFM 04 study could not be attributed to advances in alloge-
neic HSCT. Thus, we could not confirm previous studies sug-
gesting that survival rates are significantly better after alloge-
neic HSCT. The St Jude Children’s Research Hospital report-
ed 2-year OS (30 %) after allogeneic HSCT compared to 0 %
after chemotherapy alone, stating that allogeneic HSCT dur-
ing remission offers the best chance of cure [5]. The European
Group for Blood and Marrow Transplantation described that
the 3-year OS was 82 % in children after allogeneic HSCT. In
their study, also DS-AMKL patients were included, which
Table 2 5-year EFS/OS of de-
fined subgroups in AMKL
(AML-BFM 98+04)
(n=97) N Events EFS (%) P Deaths OS (%) P
Gender
Male 53 28 47±8 21 60±7
Female 44 24 47±7 0.95 18 60±8 0.92
Age, years
<2 64 35 46±6 25 60±6
2–9 23 11 50±11 8 64±10
≥10 10 6 50±16 0.93 6 48±16 0.36
WBC, 109/L
<20 75 41 46±6 31 59±6
≥20 22 11 52±11 0.87 8 65±11 0.99
BM day 15+28
≤5 % of blasts 74 34 56±6 26 66±6
>5 % of blasts 21 18 12±8 <0.001 13 35±11 0.02
Anamnesis
<3 weeks 38 15 64±8 13 69±8
≥3 weeks 53 36 31±7 0.01 25 51±7 0.23
Postremission management
Allogeneic HSCT in 1.CR 18 8 64±12 7 70±11
Chemotherapy only 59 25 57±6 0.78 21 63±6 0.85
Cytogenetics
Normal 13 5 62±13 0.30 5 60±14 0.86
Complex 25 11 55±10 0.60 7 71±9 0.17
t(1;22)(p13;q13) 8 6 38±17 0.04 4 63±17 0.30
11q23-aberrations 9 4 51±18 0.93 3 63±17 0.89
der(3) 3 1 67±27 0.50 1 67±27 0.82
+21 21 8 60±11 0.23 4 80±9 0.03
+8 16 8 56±12 0.74 6 68±12 0.62
Monosomy 7 3 2 33±27 0.57 2 33±27 0.19
Hyperdiploid 3 2 33±27 0.46 2 33±27 0.14
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confused the interpretation of the results [25]. In accordance to
Hama et al. [8], the survival rates between patients, who were
transplanted in CR1 or who received chemotherapy alone, did
not differ significantly, resulting in no proven benefit of
allogeneic HSCT in CR1 in our series for non-DS-
AMKL. Still, because of the small number of AMKL patients
with allogeneic HSCT in CR1, the results should be
interpreted carefully.
The response to induction therapy is of independent (mul-
tivariate analysis) and strong prognostic relevance. Patients
with more than 5 % bone marrow blasts on day 15 or 28 of
therapy have a poor 5-year OS of only 35±11 %. Still, the
number of non-responders could be reduced in AML-BFM 04
(8 %), compared to AML-BFM 98 (17.1 %). PCR- or flow
cytometry-based residual disease monitoring may help to dis-
tinguish between increased numbers of normal myeloblasts in
the regenerating bone marrow after chemotherapy and persis-
tence of malignant blasts to more accurately determine the
treatment response in the future [26–28].
Our cytogenetic analyses mark a difference to earlier re-
ports. Carroll et al. [9] and Duchayne et al. [10] described the
translocation t(1;22)(p13;q13) to be a good prognostic factor.
Contrarily, we demonstrated for 8 patients (10.1 % of our
cohort) a significantly lower 5-year EFS compared to patients
without this translocation. Though this may be attributable to
the small number of patients and the high NR rate, our report
puts a clear role of t(1;22) as a good prognostic indicator into
question. Interestingly, neither monosomy 7/7q-, complex
karyotype nor 11q23 aberrations indicated a poor prognosis.
A good prognostic factor in our study was gain of chromo-
some 21, which we found in 21.9 % of the patients (Supple-
mentary Fig. 2G-I). This result is represented in children, who
carried aGATA1-mutation (n=6). Based on theGATA1-status,
which is strongly associated with DS-AMKL, four of these































































































































































































































































































































































































































































































Table 4 Multivariable Cox regression analysis of clinical factors and
cytogenetics for EFS
RR 95 % CI P
Gender 1.0 0.5–2.1 0.96
Age 1.1 0.6–1.9 0.81
WBC >20x109/L 0.9 0.4–2.3 0.90
BM day 15/25, >5 % blasts 4.4 2.0–9.8 0.0003
Cytogenetics
Normal 0.6 0.2–2.1 0.47
Complex 1.1 0.4–2.9 0.84
t(1;22)(p13;q13) 3.9 0.9–16.3 0.07
+8 0.7 0.2–1.8 0.43
+21 0.7 0.3–1.9 0.50
Monosomy 7 0.4 0.1–2.5 0.35
der(3) 0.5 0.0–4.5 0.51
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previously unknown. Two patients did not have constitutional
trisomy 21, suggesting that trisomy 21was acquired as an early
step during leukemogenesis. All six patients are in continuous
remission after treatment, indicating a similar biology and
treatment response of AMKL with acquired or constitutional
(DS-AMKL) trisomy 21 in conjunction with GATA1s. There-
fore, it is crucial to perform GATA1 mutation analysis on each
patient with pediatric AMKL and it may not be advisable that
children with GATA1-mutations are stratified to the high-risk
arm of AML protocols like other AMKL patients. All children
with GATA1s-mutation showed CD7 surface marker expres-
sion, which could serve as a marker to predict the cases with
GATA1s-mutation [24]. Based on previous experience [29],
two patients of our cohort with trisomy 21 mosaic and GATA1
mutation were successfully treated with a reduced intensity
regimen for DS-AMKL patients (according to treatment rec-
ommendation of the ML-DS 2006 registry). Similar to DS-
AMKL, reduced intensity regimens seem efficient in children
with trisomy 21 mosaic and overtreatment should be avoided.
Thus, the focus on cytogenetic analyses remains of high
prognostic importance. Especially, the role of the newly de-
fined recurrent cytogenetically cryptic NUP98-JARID1A fu-
sion (t(11;15)(p15;q35)) and CBFA2T3-GLIS2-fusion
(inv(16)) needs to be addressed [30, 31]. For this reason, in-
ternational collaborative projects on pediatric non-DS-AMKL
are essential to study a broad range of chromosomal abnor-
malities, which might improve statistical analyses and there-
fore define a better risk stratification [32]. Current efforts from
the international BFM study group might address this issue.
In summary, improved intensified chemotherapy and expe-
rience of medical staff secure the step-wise and considerable
increase of long-term survival for children with non-DS de
novo AMKL. We could not prove a clear benefit for alloge-
neic HSCT in first complete remission for these patients.
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